Payment overview · 2025
General Payments
$728.11
38 reported records · 14 companies
Healthcare provider profile · identity verified
Robert E Rosemund, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, FL · NPI 1700854890
Verified facts
What the public records show
CMS Open Payments records show Robert E Rosemund, MD received $728.11 in general payments during 2025 across 38 reported records.
Novo Nordisk Inc accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Linzess, Ozempic, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $161.88 | 22.2% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $145.89 | 20.0% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $108.38 | 14.9% | 6 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $82.71 | 11.4% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $39.03 | 5.4% | 2 | 2025 |
| COLOPLAST CORP | Unresolved — no canonical attribution shown | $37.19 | 5.1% | 1 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $24.09 | 3.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.05 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.69 | 2.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $20.42 | 2.8% | 1 | 2025 |
| Corium, LLC | Unresolved — no canonical attribution shown | $19.02 | 2.6% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.47 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.56 | 2.0% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.73 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $728.11 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $145.89 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $109.09 | 6 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $82.71 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $62.78 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $62.75 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.60 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $45.60 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $45.60 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $44.97 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $43.61 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $39.03 | 2 | 2025 |
Source payment records
|
|||||
| Titan Normalized: titan |
Device | COLOPLAST CORP | $37.19 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $24.09 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.69 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $19.17 | 1 | 2025 |
Source payment records
|
|||||
| Azstarys Normalized: azstarys |
Drug | Corium, LLC | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.47 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 99 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 164 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
96 | 18 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
46 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
164 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 44 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
99 | 30 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
23 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 945 | 274 |
| Amlodipine Besylate | Amlodipine Besylate | 626 | 197 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 413 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 388 | 104 |
| Lisinopril | Lisinopril | 292 | 92 |
| Losartan Potassium | Losartan Potassium | 252 | 84 |
| Metoprolol Succinate | Metoprolol Succinate | 245 | 75 |
| Omeprazole | Omeprazole | 242 | 74 |
| Pantoprazole Sodium | Pantoprazole Sodium | 229 | 73 |
| Gabapentin | Gabapentin | 228 | 76 |
| Potassium Chloride | Potassium Chloride | 217 | 66 |
| Tramadol Hcl | Tramadol Hcl | 198 | 33 |
| Alprazolam | Alprazolam | 195 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 191 | 63 |
| Metformin Hcl Er | Metformin Hcl | 190 | 65 |
| Ozempic | Semaglutide | 189 | 44 |
| Jardiance | Empagliflozin | 164 | 43 |
| Carvedilol | Carvedilol | 155 | 48 |
| Montelukast Sodium | Montelukast Sodium | 153 | 48 |
| Clonazepam | Clonazepam | 152 | 24 |
| Prednisone | Prednisone | 151 | 75 |
| Spironolactone | Spironolactone | 150 | 40 |
| Metformin Hcl | Metformin Hcl | 145 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 53 |
| Pravastatin Sodium | Pravastatin Sodium | 134 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 46 |
| Hydrochlorothiazide | Hydrochlorothiazide | 118 | 46 |
| Simvastatin | Simvastatin | 117 | 35 |
| Sertraline Hcl | Sertraline Hcl | 116 | 42 |
| Alendronate Sodium | Alendronate Sodium | 112 | 33 |
| Finasteride | Finasteride | 112 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 106 | 30 |
| Furosemide | Furosemide | 103 | 48 |
| Buspirone Hcl | Buspirone Hcl | 101 | 29 |
| Eliquis | Apixaban | 99 | 30 |
| Synthroid | Levothyroxine Sodium | 96 | 18 |
| Trazodone Hcl | Trazodone Hcl | 95 | 28 |
| Diclofenac Sodium | Diclofenac Sodium | 94 | 38 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 37 |
| Mounjaro | Tirzepatide | 92 | 20 |
| Doxepin Hcl | Doxepin Hcl | 89 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 87 | 29 |
| Allopurinol | Allopurinol | 86 | 28 |
| Pregabalin | Pregabalin | 83 | 26 |
| Tizanidine Hcl | Tizanidine Hcl | 80 | 28 |
| Donepezil Hcl | Donepezil Hcl | 79 | 16 |
| Baclofen | Baclofen | 75 | 31 |
| Escitalopram Oxalate | Escitalopram Oxalate | 73 | 21 |
| Ipratropium Bromide | Ipratropium Bromide | 72 | 27 |
| Mirtazapine | Mirtazapine | 71 | 24 |
| Telmisartan | Telmisartan | 70 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 67 | 26 |
| Ezetimibe | Ezetimibe | 67 | 25 |
| Valsartan | Valsartan | 67 | 24 |
| Diazepam | Diazepam | 65 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 64 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 63 | 17 |
| Januvia | Sitagliptin Phosphate | 62 | 15 |
| Famotidine | Famotidine | 61 | 22 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 59 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 18 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 15 |
| Clonidine Hcl | Clonidine Hcl | 55 | 13 |
| Lovastatin | Lovastatin | 55 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 54 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 54 | 18 |
| Doxazosin Mesylate | Doxazosin Mesylate | 53 | 19 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 53 | 16 |
| Azithromycin | Azithromycin | 52 | 48 |
| Celecoxib | Celecoxib | 52 | 22 |
| Irbesartan | Irbesartan | 51 | 16 |
| Lidocaine | Lidocaine | 51 | 13 |
| Terazosin Hcl | Terazosin Hcl | 51 | 18 |
| Lansoprazole | Lansoprazole | 49 | 15 |
| Nifedipine Er | Nifedipine | 47 | 16 |
| Farxiga | Dapagliflozin Propanediol | 46 | 17 |
| Glimepiride | Glimepiride | 46 | 15 |
| Azelastine Hcl | Azelastine Hcl | 45 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 37 |
| Atenolol | Atenolol | 43 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 41 | suppressed |
| Meloxicam | Meloxicam | 39 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 16 |
| Lorazepam | Lorazepam | 36 | 11 |
| Cephalexin | Cephalexin | 35 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Glipizide Er | Glipizide | 34 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Indapamide | Indapamide | 33 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 33 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Glipizide | Glipizide | 31 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 31 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 31 | 17 |
| Ibuprofen | Ibuprofen | 30 | 13 |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 29 | suppressed |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Topiramate | Topiramate | 29 | suppressed |
| Memantine Hcl | Memantine Hcl | 28 | suppressed |
| Trulicity | Dulaglutide | 28 | suppressed |
| Bupropion Xl | Bupropion Hcl | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 19 |
| Promethazine Hcl | Promethazine Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 26 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | 13 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 24 |
| Ondansetron Odt | Ondansetron | 25 | suppressed |
| Colchicine | Colchicine | 24 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Estradiol | Estradiol | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 23 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 23 | 22 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 23 | suppressed |
| Testosterone | Testosterone | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Bumetanide | Bumetanide | 22 | suppressed |
| Torsemide | Torsemide | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Zaleplon | Zaleplon | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 21 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Primidone | Primidone | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 12 |
| Wegovy | Semaglutide | 20 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 18 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 16 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 16 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 13 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 12 | suppressed |
| Minoxidil | Minoxidil | 12 | suppressed |
| Novolog Flexpen | Insulin Aspart | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Humalog | Insulin Lispro | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $728.11 · 38 records | Novo Nordisk Inc | ABRYSVO, AREXVY, Azstarys, BREZTRI, CAPVAXIVE, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, Flexitouch Plus, GARDASIL 9, JARDIANCE, LINZESS, NURTEC ODT, Nimbl, OTEZLA, Ozempic, PREVNAR 20, REPATHA, Rybelsus, SHINGRIX, Titan, Veozah, Wegovy, XIFAXAN, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error